Abbott (ABT, $96.18) is on pace to send out 4 million new coronavirus antibody test kits this month
Abbott Laboratories said that it’s expecting to send out 4 million of its new coronavirus antibody test kits this month.
The test is designed to reveal whether a person had been infected with covid-19 and whether he or she is now asymptomatic or recovered.
“It’s clear that the demand for testing is big; it’s not going to go away.” Abbott Chief Executive Robert Ford said during an earnings conference call Thursday. (CNBC reports. ). Ford also mentioned in the call that the company plans to increase its shipments to 20 million a month starting June.
While Abbott has already introduced three coronavirus tests in the U.S., Ford indicated that a fourth one is underway.
ABT's RSI Indicator climbs out of oversold territory
The RSI Oscillator for ABT moved out of oversold territory on February 05, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 30 similar instances when the indicator left oversold territory. In of the 30 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ABT advanced for three days, in of 311 cases, the price rose further within the following month. The odds of a continued upward trend are .
ABT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 287 cases where ABT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on March 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABT as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ABT turned negative on March 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.652) is normal, around the industry mean (13.658). P/E Ratio (29.452) is within average values for comparable stocks, (41.280). Projected Growth (PEG Ratio) (2.271) is also within normal values, averaging (1.599). Dividend Yield (0.022) settles around the average of (0.020) among similar stocks. P/S Ratio (4.320) is also within normal values, averaging (35.515).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ABT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of health care products
Industry MedicalNursingServices
Advertisement